679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
If the results demonstrate significant efficacy, survodutide could represent a transformative new therapeutic option for individuals struggling with the dual burden of overweight/obesity and Type 2 Diabetes. As a dual…
Understanding Liraglutide's direct effects on inflammation could significantly broaden its therapeutic implications beyond glycemic control and weight management. If Liraglutide can effectively reduce adipose tissue i…
If liraglutide were found to be effective and safe as an add-on therapy for Type 1 Diabetes, it could represent a significant advancement in managing this complex condition. Such a finding could potentially lead to im…
Identifying predictive biomarkers for Liraglutide response could revolutionize obesity treatment by enabling personalized medicine. If successful, this research could allow clinicians to prescribe Saxenda® more effect…
Understanding how age affects Liraglutide's pharmacokinetics is crucial for optimizing treatment strategies, especially given the increasing prevalence of type 2 diabetes and obesity in the elderly population. If sign…
While this specific study did not yield results, the underlying hypothesis of combining GLP-1 agonists with increased Non-exercise Activity Thermogenesis (NEAT) remains highly relevant for optimizing Type 2 Diabetes m…
The concept behind this trial was significant: liraglutide, a GLP-1 receptor agonist, has shown potential in preserving beta-cell function and promoting their survival, which could theoretically enhance the success an…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
Oral semaglutide represents a significant advancement in Type 2 Diabetes management, offering a convenient oral alternative to injectable GLP-1 receptor agonists. Real-world studies like this are vital because they pr…
If successful, this Phase 3 trial could introduce a new, potentially effective treatment option for Type 2 Diabetes patients who require additional glycemic control beyond oral medications. A positive outcome could le…
This study is significant as it reinforces the global applicability and consistent safety profile of semaglutide for managing Type 2 Diabetes across diverse ethnic populations. Confirming its tolerability and safety i…
The daily burden of carbohydrate counting remains a significant challenge for individuals with Type 1 Diabetes, even with the most advanced closed-loop systems. If weekly Semaglutide proves effective in reducing this …
Understanding the direct haemodynamic mechanisms of semaglutide and tirzepatide is crucial for optimizing their use in patients with cardiovascular diseases. This research could reveal novel pathways through which the…
This real-world SMILE study provides compelling evidence that semaglutide 2.4 mg delivers sustained and clinically meaningful cardiometabolic benefits beyond just weight loss in a diverse patient population. The obser…
This summary from an ICER council is crucial because it provides an independent, evidence-based assessment of the clinical and economic value of two highly effective anti-obesity medications. Such reviews are instrume…
This research is crucial for identifying cognitive-behavioral markers that predict successful long-term weight loss following bariatric surgery or liraglutide treatment. Understanding these markers could lead to more …
This case report highlights a critical safety concern, suggesting that clinicians should exercise extreme caution when reinitiating GLP-1 receptor agonists like semaglutide after a treatment break. The key implication…
This review suggests a paradigm shift in treating bile acid diarrhea, moving beyond traditional bile acid sequestrants to a more targeted physiological approach. The findings strongly support further investigation int…
This review highlights the significant potential of GLP-1 RAs as a superior therapeutic option for steroid-induced diabetes, moving beyond insulin-centric approaches. Their dual benefits of improving glycemic control …
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
If the results demonstrate significant efficacy and a favorable safety profile, Survodutide could represent a substantial advancement in the treatment landscape for obesity disease in Japan. This is particularly impor…
This completed Phase 4 clinical trial represents a significant step towards optimizing care for morbidly obese patients undergoing bariatric surgery. If the results, once published, demonstrate improved preoperative h…
This study provides compelling evidence that Liraglutide offers superior benefits for endothelial function compared to Sitagliptin in patients with Type 2 Diabetes. This enhanced endothelial health could translate int…
Establishing bioequivalence is a critical regulatory step in drug development, especially when a drug's formulation changes between clinical trial phases. This ensures that the safety and efficacy data gathered in ear…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
The potential for CagriSema to offer enhanced weight loss beyond current leading therapies like semaglutide represents a significant advancement in treating obesity. If successful, this combination could provide a mor…
Understanding semaglutide's direct neurological effects in healthy individuals is profoundly important for expanding its therapeutic potential. If this study reveals positive acute cognitive or energy-enhancing effect…
This real-world study is crucial for understanding how oral semaglutide performs outside of controlled clinical trials, providing valuable insights into its effectiveness and safety in a diverse patient population und…
While this real-world study involving 388 participants is completed, specific results are pending publication. However, based on extensive prior clinical trials, oral semaglutide is known to significantly improve glyc…
The successful demonstration of feasibility and tolerability could open new avenues for managing obesity in patients with advanced lung disease, potentially improving their quality of life and clinical outcomes. If Se…
Reducing injection site pain is a critical factor for improving patient adherence to long-term therapies like Semaglutide, which is often administered weekly for chronic conditions such as Type 2 Diabetes and Obesity.…
This regulatory post-marketing surveillance study is crucial for gathering real-world evidence on oral semaglutide, complementing data from controlled clinical trials. Such data is vital for understanding how the drug…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to …
The review revealed a consistent and significant dysregulation of both orexin and GLP-1 signaling in post-viral syndromes, suggesting their central role in the manifestation of diverse symptoms. Multiple studies indic…
This review underscores the critical role of tailored dietary strategies in maximizing the therapeutic benefits of GLP-1 and dual GIP/GLP-1 receptor agonists. It suggests that integrating specific nutritional guidance…
This study provides compelling and definitive evidence that Semaglutide offers direct and substantial cardiovascular benefits in individuals with established cardiovascular disease and overweight or obesity, independe…
This landmark study provides compelling evidence that semaglutide offers significant cardiovascular protection beyond its known weight loss benefits, even in individuals without diabetes. The 20% reduction in major ad…
This study represents a paradigm shift in the management of cardiovascular risk in individuals with obesity. It unequivocally demonstrates that a GLP-1 receptor agonist, semaglutide, can directly reduce major cardiova…